<DOC>
	<DOCNO>NCT01588704</DOCNO>
	<brief_summary>The prognosis patient unresectable , locally advanced non-small cell lung cancer ( NSCLC ) poor . Chemoradiotherapy main treatment modality disease . The new drug regimen expect improve survival subset NSCLC patient . Modern target therapy enhance outcomes lung cancer treatment , especially advanced NSCLC . Among targeted approach inhibition angiogenesis bevacizumab , monoclonal antibody repress vascular endothelial growth factor ( VEGF ) . Bevacizumab combination platinum-based chemotherapy use neoadjuvant chemotherapy may change previous treatment modality . It allow lung cancer patient downstaged surgery rather radiotherapy . Thus , survival patient may improve .</brief_summary>
	<brief_title>Neoadjuvant Pemetrexed , Carboplatin Bevacizumab Unresectable , Locally Advanced Lung Adenocarcinoma</brief_title>
	<detailed_description>This trial investigate role neoadjuvant pemetrexed , carboplatin bevacizumab unresectable , locally advanced lung adenocarcinoma .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm unresectable , locally advanced ( III A ( bulky N2 ) , III B ) lung adenocarcinoma No previous chemotherapy , radiotherapy , surgery biological therapy lung cancer Adequate organ bone marrow function Prior chemotherapy radiation therapy NSCLC Prior treatment bevacizumab agent specifically target vascular endothelial growth factor ( VEGF ) Patients know hypersensitivity recombinant human antibody History stroke transient ischemic attack ( TIA ) . History myocardial infarction unstable angina within past 12 month . Other serious illness medical condition include unstable cardiac disease require treatment , history significant neurologic psychiatric disorder ( include psychotic disorder , dementia , seizure ) , symptomatic diverticulitis , active uncontrolled infection . Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>lung adenocarcinoma</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>surgical resection rate</keyword>
	<keyword>safety</keyword>
	<keyword>feasibility</keyword>
</DOC>